DFDA

Immunoglobulin (Post-exposure prophylaxis)

Treatment for Acute Hepatitis A

Typical Dosage: 0.02 mL/kg IM for typical exposures

Effectiveness
85%
Safety Score
78%
Clinical Trials
100
Participants
300K

Comparative Safety Scale(Higher is safer)

Cyanide☠ī¸
Meth💀
CigarettesđŸšŦ
Chemoâ˜ĸī¸
AlcoholđŸē
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
78
DangerousModerateSafe
Treatment Details
Dosage Range
0.02 mL/kg IM for typical exposures
Time to Effect
Immediate passive immunity
Treatment Duration
Single dose, short-term protection (weeks-months)
Evidence Quality
HIGH
Number Needed to Treat (NNT)
15(Treat 15 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
1000(Treat 1000 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$800
Side Effect Mgmt:$0
Total Annual:$1,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$75,000/QALY
QALYs Gained
0.07
Outcome-Based Costs
Cost per Responder
$235.29
Comparison vs No prophylaxis
Cost Difference
+$200/year
More expensive
QALY Difference
+0.07 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Physician Visit Cost
$100/year
Time Cost
$30/year
Travel + wait time
Insurance Admin Cost
$15/year
Prior auth, claims
Rx Price
$200/year
Risk Assessment
Misuse Risk
LOW
Missed Diagnosis Risk
LOW
Immunoglobulin (Post-exposure prophylaxis) Outcomes

for Acute Hepatitis A

Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+85%
Common Side Effects
Injection site pain
+30%
Headache
+10%
Malaise
+8%

Sources:

nih.gov
cdc.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov